Kairos Pharma Files 8-K: Other Events & Financials
Ticker: KAPA · Form: 8-K · Filed: Jul 15, 2025 · CIK: 1962011
Sentiment: neutral
Topics: regulatory-filing, financials
TL;DR
Kairos Pharma filed an 8-K for 'Other Events' and financials - details TBD.
AI Summary
Kairos Pharma, Ltd. filed an 8-K on July 15, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific details about the nature of these events or financial statements, only that they are being reported.
Why It Matters
This 8-K filing indicates that Kairos Pharma, Ltd. has made a regulatory submission concerning unspecified events and financial information, which could be material to investors.
Risk Assessment
Risk Level: medium — The filing is an 8-K, which typically reports material events, but the lack of specific details in the provided text makes it difficult to assess the immediate impact or risk.
Key Players & Entities
- Kairos Pharma, Ltd. (company) — Registrant
- July 15, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-42275 (identifier) — Commission File Number
- 46-2993314 (identifier) — IRS Employer Identification No.
- 2355 Westwood Blvd. , #139 Los Angeles CA 90064 (address) — Principal executive offices
- (310) 948-2356 (phone_number) — Registrant's telephone number
FAQ
What specific "Other Events" are being reported by Kairos Pharma, Ltd. in this 8-K filing?
The provided text of the 8-K filing does not specify the details of the "Other Events" being reported.
What is the nature of the "Financial Statements and Exhibits" mentioned in the filing?
The filing indicates that "Financial Statements and Exhibits" are part of the report, but the specific content or nature of these documents is not detailed in the provided text.
When was the earliest event reported in this Form 8-K?
The earliest event reported in this Form 8-K was on July 15, 2025.
What is Kairos Pharma, Ltd.'s principal executive office address?
Kairos Pharma, Ltd.'s principal executive office is located at 2355 Westwood Blvd. , #139 Los Angeles CA 90064.
What is the Commission File Number for Kairos Pharma, Ltd.?
The Commission File Number for Kairos Pharma, Ltd. is 001-42275.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 15, 2025 regarding Kairos Pharma, LTD. (KAPA).